Shionogi & Co. Ltd.
http://www.shionogi.co.jp/index.html
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Shionogi & Co. Ltd.
Deal Watch: AbbVie Pursues Novel Neuropsychiatric Drug Class With Gilgamesh
Plus transactions involving Sanofi/Fulcrum, Reneo/OnKure, Lilly/Mitsubishi Tanabe, Lantern/Oregon, Zydus/Eiger and more.
Maze Finds A Way As Shionogi Signs On To Develop Pompe Drug
Months after an antitrust lawsuit challenged its deal with Sanofi and raised uncertainty about the future of MZE001, Maze secured a new partner for potentially the first oral Pompe disease drug.
Shionogi: Other Countries Must Follow UK’s Lead On Antimicrobial Incentives
Shionogi’s UK general manager praised NHS England’s novel subscription model for antibiotics, but warned the country would be “wasting money” unless other global regulators introduced similar incentives for antimicrobial development.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- OTC, Consumer
-
Biotechnology
- Drug Discovery Tools
- Other Names / Subsidiaries
-
- Shionogi Healthcare Co., Ltd
- Shionogi Pharma Co., Ltd
- Shionogi Techno Advance Research Co., Ltd.
- Shionogi Administration Service Co., Ltd.
- Shionogi Business Partner Co., Ltd
- Shionogi Marketing Solutions Co., Ltd
- Shionogi Career Development Center Co., Ltd.
- Shionogi Digital Science Co., Ltd.
- Shionogi Pharmacovigilance Center Co., Ltd.
- Aburahi AgroResearch Co., Ltd.
- Shionogi Smile Heart Co., Ltd
- UMN Pharma Inc.
- Shionogi B.V.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice